CG Oncology IPO rockets 85% in sign of pent-up deal demand
The cancer-drug company CG Oncology Inc. priced its initial public offering above its estimated range and added 3 million shares to the deal, in a bullish sign ahead of its trading debut Thursday on the Nasdaq.